CY2017029I2 - ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ - Google Patents
ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣInfo
- Publication number
- CY2017029I2 CY2017029I2 CY2017029C CY2017029C CY2017029I2 CY 2017029 I2 CY2017029 I2 CY 2017029I2 CY 2017029 C CY2017029 C CY 2017029C CY 2017029 C CY2017029 C CY 2017029C CY 2017029 I2 CY2017029 I2 CY 2017029I2
- Authority
- CY
- Cyprus
- Prior art keywords
- trifluorothymidine
- anticancer drug
- drug containing
- phosphorylase inhibitor
- thymidine phosphorylase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2017029I1 CY2017029I1 (el) | 2018-02-14 |
| CY2017029I2 true CY2017029I2 (el) | 2018-02-14 |
Family
ID=36740357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2017029C CY2017029I2 (el) | 2005-01-26 | 2017-09-07 | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ |
| CY20171100947T CY1119393T1 (el) | 2005-01-26 | 2017-09-07 | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100947T CY1119393T1 (el) | 2005-01-26 | 2017-09-07 | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (show.php) |
| JP (1) | JP5576591B2 (show.php) |
| KR (1) | KR101468216B1 (show.php) |
| AU (1) | AU2006209547C1 (show.php) |
| BE (1) | BE2017C028I2 (show.php) |
| CA (1) | CA2594713A1 (show.php) |
| CY (2) | CY2017029I2 (show.php) |
| DK (1) | DK1849470T4 (show.php) |
| ES (1) | ES2630002T5 (show.php) |
| FI (1) | FI1849470T4 (show.php) |
| FR (1) | FR17C1028I2 (show.php) |
| HU (2) | HUE033306T2 (show.php) |
| LT (2) | LT1849470T (show.php) |
| LU (1) | LUC00036I2 (show.php) |
| NL (1) | NL300889I2 (show.php) |
| PL (1) | PL1849470T5 (show.php) |
| PT (1) | PT1849470T (show.php) |
| RU (1) | RU2394581C2 (show.php) |
| SI (1) | SI1849470T2 (show.php) |
| TW (1) | TWI362265B (show.php) |
| WO (1) | WO2006080327A1 (show.php) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| EP1849470B2 (en) | 2005-01-26 | 2024-03-20 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| ES2587381T3 (es) * | 2007-04-25 | 2016-10-24 | Cyclacel Limited | Uso de sapacitabina para tratar una enfermedad proliferativa |
| CA2713128C (en) | 2008-01-25 | 2016-04-05 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| PT2273983T (pt) | 2008-05-09 | 2016-10-28 | Gruenenthal Gmbh | Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização |
| EP2303283A2 (en) * | 2008-05-15 | 2011-04-06 | Katholieke Universiteit Leuven K.U. Leuven R&D | Anti-cancer combination therapy |
| PE20120572A1 (es) | 2009-07-22 | 2012-06-06 | Gruenenthal Chemie | Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion |
| BR112012001547A2 (pt) | 2009-07-22 | 2016-03-08 | Gruenenthal Gmbh | forma de dosagem farmacêutica extrusada por fusão a quente |
| MX2013002377A (es) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a manipulacion que comprende una sal inorganica. |
| AU2011297892B2 (en) | 2010-09-02 | 2014-05-29 | Grunenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| NO2736495T3 (show.php) | 2011-07-29 | 2018-01-20 | ||
| MX348054B (es) | 2011-07-29 | 2017-05-25 | Gruenenthal Gmbh | Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco. |
| EP2746404B1 (en) | 2011-08-16 | 2017-12-06 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer |
| TWI503122B (zh) | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| CA2864949A1 (en) | 2012-02-28 | 2013-09-06 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| TWI585206B (zh) | 2012-03-14 | 2017-06-01 | Nisshin Pharma Inc | A method for producing a composition containing a sulfur-containing amino acid |
| PT2838512T (pt) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| CN104349779A (zh) * | 2012-05-16 | 2015-02-11 | 诺华股份有限公司 | Pi-3激酶抑制剂的剂量方案 |
| KR101847252B1 (ko) * | 2013-03-27 | 2018-04-09 | 다이호야쿠힌고교 가부시키가이샤 | 이리노테칸염산염 수화물을 함유하는 항종양제 |
| EP2979700B1 (en) * | 2013-03-27 | 2018-09-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including low dose irinotecan hydrochloride hydrate |
| TWI595879B (zh) * | 2013-05-17 | 2017-08-21 | 大鵬藥品工業股份有限公司 | Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity |
| WO2014191397A1 (en) | 2013-05-29 | 2014-12-04 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
| LT3042669T (lt) | 2013-09-06 | 2023-06-26 | Taiho Pharmaceutical Co., Ltd. | Priešvėžinis agentas ir stipriklis su priešvėžiniu poveikiu |
| MX371372B (es) | 2013-11-26 | 2020-01-28 | Gruenenthal Gmbh | Preparacion de una composicion farmaceutica en polvo por medio de criomolienda. |
| CN106572980A (zh) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | 包含他喷他多的防篡改即释胶囊制剂 |
| MX2016015417A (es) | 2014-05-26 | 2017-02-22 | Gruenenthal Gmbh | Multiparticulas protegidas contra vertido de dosis etanolico. |
| AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
| EP3693019A1 (en) * | 2016-01-08 | 2020-08-12 | Taiho Pharmaceutical Co., Ltd. | Anti-tumor agent containing immunomodulator |
| NZ745113A (en) | 2016-02-05 | 2021-12-24 | Taiho Pharmaceutical Co Ltd | Method for treating cancer patients with severe renal impairment |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US20260021045A1 (en) * | 2024-07-17 | 2026-01-22 | Jnd Therapeutics, Inc. | Methods and formulations for treatment of liver cancer using trifluridine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2191340C (en) * | 1995-03-29 | 2001-04-17 | Shingo Yano | Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same |
| US6255314B1 (en) * | 1996-09-24 | 2001-07-03 | Taiho Charmaceutical Co., Ltd. | Cancerous metastasis inhibitors containing uracil derivatives |
| EP1849470B2 (en) | 2005-01-26 | 2024-03-20 | Taiho Pharmaceutical Co., Ltd. | Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor |
-
2006
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en not_active Expired - Lifetime
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en not_active Expired
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja not_active Expired - Lifetime
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es not_active Expired - Lifetime
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko not_active Expired - Lifetime
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017029I2 (el) | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ | |
| DE112006001565A5 (de) | Nanopartikel-Wirkstoff-Konjugate | |
| DK1907037T3 (da) | Medikamentdispenser. | |
| DE602005020310D1 (de) | Lanzette, lanzettenanordnung und lanzette-sensor-kombination | |
| DK2046715T3 (da) | Substituerede 1,3-diphenylpropanderivater, præparater og anvendelser deraf | |
| EP1863864A4 (en) | RETICULABLE BIOPOLYMER | |
| EP1992348A4 (en) | PHARMACEUTICAL COMBINATION | |
| RU2398586C3 (ru) | Фармацевтическая композиция | |
| DK2034015T3 (da) | Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf | |
| BRPI0715342A2 (pt) | Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos | |
| DK1957073T3 (da) | Lægemiddel | |
| DK1757293T3 (da) | Bh4-responsiv hyperphenylalaninæmi-medikamenter | |
| EP2076125A4 (en) | MODIFIED NDGA DERIVATIVES FROM TETRA-O-SUBSTITUTED BUTANE BRIDGE, THEIR SYNTHESIS AND PHARMACEUTICAL USE | |
| DE602005020457D1 (de) | Master-slave-flip-flop, trigger-flip-flop und zähler | |
| DK1745786T3 (da) | Neuroprotektive forbindelser og farmaceutiske præparater, som omfatter dem | |
| IL186851A0 (en) | Styrylsulfonamides, their manufacture and use as pharmaceutical agents | |
| BRPI0614413A2 (pt) | composto, e, composição farmacêutica | |
| EP1941909A4 (en) | PREVENTIVE MEASURES / REMEDIES FOR CANCER | |
| ATE420118T1 (de) | Biotinylierte hexadecasaccharide, pharmazeutische zusammensetzungen daraus und deren verwendung | |
| BRPI0614412A2 (pt) | composto, e, composição farmacêutica | |
| IL187419A0 (en) | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents | |
| DE602006017569D1 (de) | Pharmazeutische kombinationen mit lamivudin, stavudin und nevirapin | |
| DK1944298T3 (da) | Quinazolinderivat og lægemiddel | |
| ITBO20050248A1 (it) | Prodotto per distanziare e bloccare le arcate dentarie | |
| HK1113133A (en) | Substituted oxindol derivatives, drugs containing said derivatives and the use thereof |